Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-010085
Filing Date
2022-05-16
Accepted
2022-05-16 16:18:36
Documents
52
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20220331.htm   iXBRL 10-Q 1057701
2 EX-31.1 ikt-ex31_1.htm EX-31.1 16413
3 EX-31.2 ikt-ex31_2.htm EX-31.2 16432
4 EX-32.1 ikt-ex32_1.htm EX-32.1 13767
5 EX-32.2 ikt-ex32_2.htm EX-32.2 13767
  Complete submission text file 0000950170-22-010085.txt   3632676

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20220331.xsd EX-101.SCH 32807
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20220331_lab.xml EX-101.LAB 258635
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20220331_def.xml EX-101.DEF 89938
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20220331_cal.xml EX-101.CAL 22191
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20220331_pre.xml EX-101.PRE 186898
46 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20220331_htm.xml XML 404597
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 22929374
SIC: 2836 Biological Products, (No Diagnostic Substances)